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Abstract
Background: Colorectal cancer (CRC) is one of the most common causes of cancer-related
deaths in the Western world, and despite the fact that metastases are usually the ultimate cause of
deaths, the knowledge of the genetics of advanced stages of this disease is limited. In order to
identify potential genetic abnormalities underlying the development of local and distant metastases
in CRC patients, we have, by comparative genomic hybridization, compared the DNA copy number
profiles of 10 primary carcinomas, 14 local recurrences, 7 peritoneal carcinomatoses, and 42 liver
metastases from 61 CRC patients.
Results: The median number of aberrations among the primary carcinomas, local recurrences,
carcinomatoses, and liver metastases was 10, 6, 13, and 14, respectively. Several genetic imbalances,
such as gains of 7, 8q, 13q, and 20, and losses of 4q, 8p, 17p, and 18, were common in all groups.
In contrast, gains of 5p and 12p were more common in the carcinomatoses than in other stages of
the disease. With hierarchical cluster analysis, liver metastases could be divided into two main
subgroups according to clusters of chromosome changes.
Conclusions: Each stage of CRC progression is characterized by a particular genetic profile, and
both carcinomatoses and liver metastases are more genetically complex than local recurrences and
primary carcinomas. This is the first genome profiling of local recurrences and carcinomatoses, and
gains of 5p and 12p seem to be particularly important for the spread of the CRC cells within the
peritoneal cavity.
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Background
More than a decade ago, a genetic model for the ade-
noma–carcinoma sequence in the large bowel was pre-
sented by Fearon and Vogelstein [1]. It is now widely
accepted that colorectal cancer (CRC) arises through the
accumulation of genetic and epigenetic changes [2]. The
order as well as the number of events are important in the
process that transform normal cells into neoplastic pre-
cursors and subsequently into malignant tumors, which
may further metastasize [3]. Inactivation of tumorsupres-
sor genes, APC and TP53, as well as components of mis-
match repair system, is commonly found in colorectal
tumors. A recent study suggest alternative molecular path-
ways for colorectal carcinomas based on the observation
that APC, KRAS2, and TP53 are all frequently mutated but
rarely in the same tumor [4]. Twelve to fifteen percent of
all primary colorectal carcinomas display microsatellite
instability [5-8], a result of defect mismatch repair [9]. The
majority of colorectal carcinomas, however, harbor
numerous aberrations at the chromosome level, and chro-
mosomal instability seems to be pronounced in these
tumors [2]. This type of instability may be caused by var-
ying mechanisms, including telomer dysfunction, defect
DNA double-strand break repair and disturbances during
chromosome segregation [10].
The genomes of hundreds of primary colorectal carcino-
mas have now been studied by conventional chromo-
somal banding technique as well as by comparative
genomic hybridization (CGH) [11-28]. These studies
have revealed a nonrandom pattern of genomic abnor-
malities in primary carcinomas, including frequent gain
of material from chromosomes and chromosome arms 7,
8q, 13, and 20, and losses from 4, 8p, 14, 17p, and 18q.
However, in spite of the fact that metastases are usually
the ultimate cause of death in CRC patients [29], the
cytogenetic changes that characterize and presumably
drive the advanced stages of this disease have been poorly
described [reviewed in [25,30]]. We have recently ana-
lyzed 17 CRC liver metastases, combining chromosome
banding with CGH, and found that the former technique,
in contrast to CGH profiles, did not always detect the
cytogenetically abnormal clones [30]. The use of CGH
have provided profiles of various series of liver metastases
[reviewed in [30]]. To our knowledge the genome aberra-
tions in local recurrences and peritoneal carcinomatoses
from CRC patient have not previously been described. In
order to identify genetic changes underlying the develop-
ment of local and distant metastases, we have compared
the genomes of primary CRC with those of local recur-
rences, peritoneal carcinomatoses, and liver metastases
using a molecular cytogenetic approach.
Results
The complete CGH profiles are presented in the supple-
mentary Table 1 (additional data file 1). All tumors,
except one primary carcinoma, three local recurrences and
one liver metastasis, exhibited DNA copy number
changes, and the overall copy number profiles for each
tumor stage are illustrated in Fig. 1. The number of imbal-
ances per case ranged from 0 to 28 (median, 11).
Although all chromosomes were involved, the distribu-
tion of the imbalances was clearly nonrandom. The most
common copy number changes, found in more than 20%
of each tumor group, were gains of 7, 8q, 13q, and 20, and
losses of 4q, 8p, 17p, and 18, but however, frequency var-
iations were observed among primary tumors, local recur-
rences, and liver metastases (Fig. 1). Twenty tumors
showed amplifications (Table 1, supplementary data,
additional data file 1) in one to nine discrete regions:
chromosome arms 13q (ten cases), 20q (nine cases), 8q
(eight cases), 20p (six cases), 5p (one case), and chromo-
some X (two cases) and 7 (one case). The frequency of
amplification did not differ significantly among the differ-
ent tumor groups.
The number of imbalances per case for primary carcino-
mas, local recurrences, carcinomatoses, and liver metas-
tases ranged from 0 to 16 (median, 10), 0 to 17 (median,
6), 1 to 20 (median, 13), and 0 to 28 (median, 14),
respectively. Increased copy numbers of chromosome
arms 5p and 12p were significantly more frequent in the
carcinomatoses than in the other lesions, except the asso-
ciation for 5p between carcinomatoses and primary carci-
nomas (Table 1).
A hierarchical cluster analysis was performed for the
colorectal tumors based on the gains and losses from all
chromosome arms (Fig. 2). No chromosome changes
seemed to be tumor-stage specific. Furthermore, a sepa-
rate cluster analysis for the 37 liver metastases is
illustrated in Fig. 3. The majority of the liver metastases
harbored changes at 7, 8p, 13q, 17p, 18, and 20 (pink
tree). The top dendogram indicates that the liver
metastases can be subdivided into two main groups (red
and brown trees) according to the chromosome changes,
one of these subgroup is characterized by additional
changes at 4q, 5q, 6p, 8q, 16 (blue tree).
In four of the five patients from whom both primary car-
cinomas and liver metastases were analyzed, the liver
metastases had more aberrations than the corresponding
primary carcinomas (Table 1, supplementary data, addi-
tional data file 1). Gains of 8q (four cases) and 20q (three
cases), and losses of 8p (three cases) and 18q (three cases)
were seen in both the primary carcinomas and metastatic
samples, whereas gain of 7p and loss of 15q were moreMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/6
Page 3 of 9
(page number not for citation purposes)
common in the liver metastases than in the primary
carcinomas (7p: in 5 metastases versus 2 primary carcino-
mas; 15q: in 4 metastases versus 1 primary carcinoma).
Discussion
The present study is the first CGH study of peritoneal car-
cinomatoses and local recurrences from CRC patients and
includes one of the largest series of liver metastases ana-
lyzed. Our data provide clues to the understanding of the
Graphic comparison of the overall genomic gains (A) and losses (B) detected by CGH in different CRC stages Figure 1
Graphic comparison of the overall genomic gains (A) and losses (B) detected by CGH in different CRC stages. 
For each case, the presence or absence of imbalance in every chromosome band (from 1p36 to Xq28) was computed in a 
spreadsheet. The total number of imbalances detected in every band was then used to prepare the graphic comparison. All 
chromosome arms were involved in imbalances. (A) Loss of 18q was one of the most frequent aberrations seen in all groups. 
In addition to 18q loss, primary carcinomas and liver metastases often showed loss of 8p. Additionally, liver metastases and car-
cinomatoses frequently harbored loss of 4q. (B) Gain of 8q and 20q were common in all tumor types. In addition, carcinoma-
toses often contained gains of 5p, 7p, 9q, 12, and 13q, whereas liver metastases often showed gains of 7p, and 13q. * Multiple 
samples from a single tumor (case no. 53R1 and 53R2; 64C1 and 64C2; 21L1 and 21L2; 42L1 and 42L2; 52L1 and 52L2; 76L1, 
76L2, and 76L3) were counted as one sample.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/6
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genetic basis of the advanced disease stages. Local recur-
rences are re-growth of tumor cells at the site of the pri-
mary carcinomas. We found that the median number of
alterations in these tumors was lower than in the primary
carcinomas. In a heterogeneous primary tumor, regrowth
to a local recurrency might originate from genetically less
complex cells in the primary tumor. This observation
should be interpreted with caution since the analyzed pri-
mary carcinomas and local recurrences were not from the
same patients, and in fact the ranges of aberrations were
large for both tumor groups.
Peritoneal carcinomatosis reflects the regional spread of
cancer cells within the peritoneal cavity. Although carci-
nomatosis is not always associated with widespread vis-
ceral or extra-peritoneal disease, it almost always reflects
an incurable disease [31,32]. The present comparisons of
the distribution and frequency of specific chromosomal
imbalances among the different tumor stages revealed sig-
nificant differences between carcinomatoses and each of
the other stages of the disease regarding gains at 5p and
12p (Table 1). The frequencies of 5p gains were not signif-
icantly different between primary carcinomas and carci-
nomatoses (Table 1), is best explained by small sample
sets. However, these chromosome aberrations are indeed
quite rare in primary colorectal carcinomas as evaluated
from previous studies, and among 670 cases the average
frequencies for 5p and 12p gains were less than 10% each
[11-23,28,33-40]. Summarized, the present study and the
previous data, lead us to speculate that genes located at
these chromosome arms are involved in development of
peritoneal carcinomatoses. Although gain of 5p12-p14
was confirmed in both samples from the same patient
(Fig. 4), a smallest region of overlapping gain can not
determined from one case only.
Our findings agree well with previous CGH studies of pri-
mary colorectal carcinomas and liver metastases, as the
type and the frequency of copy number changes are
comparable [11-23,28,30,33-42]. The increasing number
of aberrations found in distant metastases compared to
primary carcinomas is also in line with a previous allelo-
type study in which we found a higher fractional allelic
imbalance in liver metastases than in primary carcinomas
and local recurrences [43].
Some observation from the results obtained from the five
primary carcinomas and their corresponding liver metas-
tases are worth mentioning. Gain of 7p and loss of 15q
were more frequent in the latter, and interestingly the
three primary carcinomas that each showed one of these
aberrations had synchronous liver metastases. When the
present cases and those of previous reports were com-
bined [11-23,28,41,42], statistical significant frequency
differences between these two stages were found (7p: 216/
670 versus 74/147, P < 0.001; 15q: 114/670 versus 39/147,
P < 0.001), indicating that 7p gains and 15q losses may be
involved in the development of distant metastases.
Losses involving chromosomes 17 and 18 were seen in 19
(31%) and 42 (69%), respectively, of the cases in the
present study. These changes have been suggested to be
late and important events in the adenoma-carcinoma
sequence [1], as they have been shown to be more fre-
quent in carcinomas than in adenomas [24,44,45]. Dele-
tions of 17p and 18q usually reflect inactivation of TP53
[1], DCC [46], MADH2, and MADH4 [46,47]. Changes at
chromosome 8, usually loss of 8p and gain of 8q, are
important late events in colorectal carcinogenesis, and
occur more often in carcinomas and metastases than in
adenomas [15,24,44]. Deletions of 8p, 17p, and 18q and
inactivation of their potential target genes are associated
with short survival [48,49], again supporting their impor-
tant role in the disease progression.
The present study showed that gains of 13q and 20q are
also frequent in the late stages of CRC (73% and 89%,
respectively). Increased copy number of chromosome arm
13q, often reflecting trisomy of chromosome 13, is also
found as the sole aberration in colorectal adenomas [25],
suggesting this to be an early event in colorectal tumori-
genesis. Gain of 20q is an aberration frequently seen in
carcinomas and less commonly in adenomas [15]. In an
assessment of the clonal composition of colorectal
Table 1: Imbalances of 5p and 12p in the different stages of CRC.
Chromosome arms 5p 12p
Tumor types Gain/Total Pa Gain/Total Pa
Carcinomatoses 4/6b 4/6b
Primary carcinomas 3/10 0.302 1/10 0.036
Recurrences 1/13bb 0.017 1/13b 0.017
Liver metastases 5/37b 0.012 6/37b 0.020
a Comparison between carcinomatoses and the other stages of the CRC were performed using two-sided Fisher exact test. b Multiple samples from 
the same tumor were counted as one sample.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/6
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Hierarchical clustering of tumors from different stages of colorectal cancer Figure 2
Hierarchical clustering of tumors from different stages of colorectal cancer. The hierarchical clustering is based on 
chromosome aberrations of all chromosome arms. Chromosome arms 13p, 14p, 15p, 21p, 22p, and chromosome Y, due to 
high content of heterochromatin, were excluded from the cluster analysis. The chromosome arms are given in the right dendo-
gram (gains in green and losses in blue). Each tumor sample is depicted and coded (white – primary carcinomas; yellow – local 
recurrence; green – peritoneal carcinomatoses; red – liver metastases) at the top of the dendogram. Each row represents the 
alterations from a separate chromosome arm over all tumor samples, and each column represents all changes in each tumor.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/6
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adenomas using FISH analyses with centromere probes,
we found that 7, 13, and 20 were present with >2 signals
in at least 1/3 of the adenomas [50]. This and the present
results reveal a major cluster of changes in all advanced
stages (containing gains of 7, 13q, 20q, and losses of 8p,
17p and 18q), one may therefore speculate that gains of 7,
13q, and 20q precede the losses of 8p, 17p, 18q, and all
aberrations seem to be, in most cases, part of the clone
within the primary tumor with the ability to metastasize,
locally and peripheral.
Conclusions
A number of genetic imbalances common to all tumor
groups were demonstrated, as well as consistent genetic
differences among the different stages. Whereas local
recurrences were genetically less complex than primary
colorectal carcinomas, liver metastases and peritoneal
carcinomatoses usually have more DNA copy number
changes than the lesions from which they originated.
Gains of 5p and 12p seem to be particularly important for
the spread of CRC cells within the peritoneal cavity.
Hierarchical clustering of liver metastases from colorectal  cancer patients Figure 3
Hierarchical clustering of liver metastases from 
colorectal cancer patients. The hierarchical clustering is 
based on chromosome aberrations of all chromosome arms. 
Chromosome arms 13p, 14p, 15p, 21p, 22p, and chromo-
some Y, due to high content of heterochromatin, were 
excluded from the cluster analysis. The chromosome arms 
are given in the right dendogram (gains in green and losses in 
blue). Each tumor sample is depicted at the top of the dendo-
gram. Each row represents alterations from a separate chro-
mosome arm over all tumor samples, and each column 
represents all changes in each tumor.
Gains of 5p and 12p in carcinomatoses Figure 4
Gains of 5p and 12p in carcinomatoses. Gains of 5p 
(samples 17C, 64C1, and 64C2) and 12p (samples 36C, 
64C1, and 62C2) were clearly detected by CGH. The central 
line (red) in the CGH profile shows the average fluorescence 
ratio along the chromosome, and the flanking curves (brown) 
represent the 95% confidence interval. The red and the 
green lines represent the cut-off values, 0.83 and 1.17, 
respectively.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/6
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Material and methods
Patients and tumor samples
Ten primary carcinomas, 14 local recurrences, 7 perito-
neal carcinomatoses, and 42 liver metastases from 61 CRC
patients admitted to the Norwegian Radium Hospital
(Oslo, Norway) and to the Lund University Hospital
(Lund, Sweden), were included in the present study. Both
primary carcinomas and liver metastases were obtained
from each of five patients. Among these, three (76, 93,
136) occurred synchronously and two (3, 112)
metachronously.
From each frozen tumor sample, a five µm section was
stained with hematoxylin and eosin and evaluated by a
pathologist (J. M. N.). The tumor area was identified, and
dissected to enrich the fraction of tumor cells before DNA
extraction, which was performed using standard phenol
and chloroform extraction followed by ethanol precipita-
tion [51] (nucleic acid extractor, Model 340A, Applied
Biosystems, Foster City, CA).
CGH analysis
The CGH method initially described by Kallioniemi et al.
[52] was used with modifications previously described by
Kraggerud et al. [53]. Briefly, test (tumor) and reference
(peripheral blood lymphocytes from 4 healthy females or
4 healthy males) DNA were labeled in nick-translation
reactions with a mixture of two fluorochrome-conjugated
nucleotides (FITC-12-dCTP and FITC-12-dUTP for tumor
DNA, and Texas Red-6-dCTP and Texas Red-6-dUTP for
reference DNA, New England Nuclear, Boston, MA). The
same amounts of labeled tumor and reference DNA (1 µg
each) were mixed with 20 µg of unlabeled Cot-1 DNA
(Life Technologies, Rockville, MD), ethanol-precipitated,
dried, and dissolved in hybridization buffer (Vysis,
Downers Grove, IL). Normal metaphase cells were
obtained from lymphocyte culture from healthy donors.
After denaturing, the DNA was hybridized to normal,
denatured metaphase spreads and incubated in a humid-
ified chamber for 2–3 days at 37°C. Finally, the slides
were washed and mounted in an antifade solution with
DAPI (Vector Laboratories, Burlingame, CA). Good-qual-
ity metaphase spreads were selected. Three images – FITC
(green) and Texas Red (red) hybridization signals and
DAPI counterstain – were sequentially captured with a
Cohu 4900 CCD (12 bits gray scale) camera, using an
automated filter wheel coupled to a Zeiss Axioplan
fluorescence microscope (Zeiss, Oberkochen, Germany),
and a CytoVision system (Applied Imaging, Newcastle,
UK). Chromosomes were identified based on their
inverted DAPI banding, and fluorescence ratio profiles
(green to red fluorescence) were calculated for each chro-
mosome using data from at least eight representative cop-
ies of each chromosome (range 8 – 22). Average ratio
profiles with 95% confidence intervals were generated for
each tumor. The Y chromosome was not evaluated. Due to
the high quality DNA extracted from frozen tissue, the
threshold values 1.17 and 0.83 were used to score gain
and loss of DNA sequences, respectively. This threshold
allows the detection of one chromosome copy number
change present in at least 50% of the cells in a sample
from a triploid tumor. Amplification was defined as a
ratio equal to or above 2.0, corresponding to the detection
of at least 6 and 9 chromosomes in 50% of the cells in a
diploid and triploid tumor, respectively. All scorings were
performed independently by two of the authors (C. B. D.
and R. A. L.) with few interobserver differences; these were
resolved after joint reevaluation. A negative (normal ver-
sus normal) and a positive (the colon cell line LoVo with
known copy number changes) control was included in
every set of experiments. The description of the CGH copy
number changes followed the guidelines suggested in the
International System for Human Cytogenetic Nomencla-
ture [54]. In order to distinguish between a CGH profile
that was abnormal throughout the chromosome from one
that returns to normal within the terminal band, we used
"ter" in the former and the respective band number in the
latter when writing the copy number changes. CGH pro-
files for 17 of the liver metastases have previously been
published [30].
Statistical analyzes
For hierarchical clustering the average-linkage method
was used with Pearson's correlation similarity measure.
The cluster analyses and the drawing of the dendogram
were performed with J-Express Pro [55]. For comparisons
of different groups, the two-sided Fisher exact test was
used, and all the statistical analyzes were performed with
the SPSS© software (SPSS, Chicago, IL).
Abbreviations
CGH, comparative genomic hybridization; CRC, colorec-
tal cancer.
Authors' contributions
CBD, LT, and ME carried out the experimental work. CBD
interpreted the result, performed bioinformatics and sta-
tistical analyses and drafted the manuscript. MRT partici-
pated in the evaluation of the cytogenetic data and in the
manuscript preparation. JNW, K-EG, and BJ were respon-
sible for referring the patients, collecting tissue specimens
and clinical information. JMN determined the histologi-
cal diagnoses. RAL conceived the study, was responsible
for its design and coordination, participated in the
evaluation of the data and in the manuscript preparation.
All authors read and approved the final version.Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/6
Page 8 of 9
(page number not for citation purposes)
Additional material
Acknowledgements
The technical assistance of Merete Hektoen for DNA extraction is grate-
fully acknowledged. This work was supported by a PhD grant (CBD) from 
the Norwegian Foundation for Health and Rehabilitation (CBD), as well as 
grants from the Norwegian Cancer Society (LT, RAL), and the Swedish 
Cancer Society (BJ).
References
1. Fearon ER, Vogelstein B: A genetic model for colorectal
tumorigenesis. Cell 1990, 61:759-767.
2. Lengauer C, Kinzler KW, Vogelstein B: Genetic instability in
colorectal cancers. Nature 1997, 386:623-627.
3. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal
cancer. Cell 1996, 87:159-170.
4. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Gar-
ner RC, Steele RJ, Wolf CR: Mutations in APC, Kirsten-ras, and
p53--alternative genetic pathways to colorectal cancer. Proc
Natl Acad Sci USA 2002, 99:9433-9438.
5. Aaltonen LA, Pennanen S, Leach FS, Sistonen P, Pylkkanen L, Mecklin
JP, Jarvinen H, Powell SM, Jen J, Hamilton SR: Clues to the patho-
genesis of familial colorectal cancer. Science 1993, 260:812-816.
6. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M: Ubiqui-
tous somatic mutations in simple repeated sequences reveal
a new mechanism for colonic carcinogenesis.  Nature 1993,
363:558-561.
7. Lothe RA, Peltomäki P, Meling GI, Aaltonen LA, Nystrom-Lahti M,
Pylkkanen L, Heimdal K, Andersen TI, Møller P, Rognum TO:
Genomic instability in colorectal cancer: relationship to clin-
icopathological variables and family history. Cancer Res 1993,
53:5849-5852.
8. Thibodeau SN, Bren G, Schaid DJ: Microsatellite instability in
cancer of the proximal colon. Science 1993, 260:816-819.
9. Fishel R, Kolodner RD: Identification of mismatch repair genes
and their role in the development of cancer. Curr Opin Genet
Dev 1995, 5:382-395.
10. Albertson DG, Collins C, McCormick F, Gray JW: Chromosome
aberrations in solid tumors. Nat Genet 2003, 34:369-376.
11. Al-Mulla F, Keith WN, Pickford IR, Going JJ, Birnie GD: Compara-
tive genomic hybridization analysis of primary colorectal
carcinomas and their synchronous metastases. Genes Chromo-
somes Cancer 1999, 24:306-314.
12. Paredes-Zaglul A, Kang JJ, Essig YP, Mao W, Irby R, Wloch M, Yeat-
man TJ: Analysis of colorectal cancer by comparative
genomic hybridization: evidence for induction of the meta-
static phenotype by loss of tumor suppressor genes. Clin Can-
cer Res 1998, 4:879-886.
13. De Angelis PM, Clausen OP, Schjolberg A, Stokke T: Chromosomal
gains and losses in primary colorectal carcinomas detected
by CGH and their associations with tumour DNA ploidy,
genotypes and phenotypes. Br J Cancer 1999, 80:526-535.
14. De Angelis PM, Stokke T, Beigi M, Mjaland O, Clausen OP: Prognos-
tic significance of recurrent chromosomal aberrations
detected by comparative genomic hybridization in sporadic
colorectal cancer. Int J Colorectal Dis 2001, 16:38-45.
15. Ried T, Knutzen R, Steinbeck R, Blegen H, Schrock E, Heselmeyer K,
du Manoir S, Auer G: Comparative genomic hybridization
reveals a specific pattern of chromosomal gains and losses
during the genesis of colorectal tumors. Genes Chromosomes
Cancer 1996, 15:234-245.
16. Aust DE, Willenbucher RF, Terdiman JP, Ferrell LD, Chang CG,
Moore DH, Molinaro-Clark A, Baretton GB, Loehrs U, Waldman FM:
Chromosomal alterations in ulcerative colitis-related and
sporadic colorectal cancers by comparative genomic
hybridization. Hum Pathol 2000, 31:109-114.
17. Nakao K, Shibusawa M, Tsunoda A, Yoshizawa H, Murakami M,
Kusano M, Uesugi N, Sasaki K: Genetic changes in primary color-
ectal cancer by comparative genomic hybridization.  Surg
Today 1998, 28:567-569.
18. Nakao K, Shibusawa M, Ishihara A, Yoshizawa H, Tsunoda A, Kusano
M, Kurose A, Makita T, Sasaki K: Genetic changes in colorectal
carcinoma tumors with liver metastases analyzed by com-
parative genomic hybridization and DNA ploidy. Cancer 2001,
91:721-726.
19. Schlegel J, Stumm G, Scherthan H, Bocker T, Zirngibl H, Ruschoff J,
Hofstadter F: Comparative genomic in situ hybridization of
colon carcinomas with replication error.  Cancer Res 1995,
55:6002-6005.
20. Aragane H, Sakakura C, Nakanishi M, Yasuoka R, Fujita Y, Taniguchi
H, Hagiwara A, Yamaguchi T, Abe T, Inazawa J, Yamagishi H: Chro-
mosomal aberrations in colorectal cancers and liver metas-
tases analyzed by comparative genomic hybridization. Int J
Cancer 2001, 94:623-629.
21. Meijer GA, Hermsen MA, Baak JP, van Diest PJ, Meuwissen SG, Belien
JA, Hoovers JM, Joenje H, Snijders PJ, Walboomers JM: Progression
from colorectal adenoma to carcinoma is associated with
non-random chromosomal gains as detected by compara-
tive genomic hybridisation. J Clin Pathol 1998, 51:901-909.
22. Rooney PH, Murray GI, Stevenson DA, Haites NE, Cassidy J, McLeod
HL: Comparative genomic hybridization and chromosomal
instability in solid tumours. Br J Cancer 1999, 80:862-873.
23. Knösel T, Petersen S, Schwabe H, Schluns K, Stein U, Schlag PM, Die-
tel M, Petersen I: Incidence of chromosomal imbalances in
advanced colorectal carcinomas and their metastases. Vir-
chows Arch 2002, 440:187-194.
24. Bardi G, Sukhikh T, Pandis N, Fenger C, Kronborg O, Heim S: Kary-
otypic characterization of colorectal adenocarcinomas.
Genes Chromosomes Cancer 1995, 12:97-109.
25. Mitelman F, Johansson B, Mertens F: Mitelman database of chro-
mosome aberrations in cancer. http://cgap nci nih gov/Chromo-
somes/Mitelman 2003.
26. Mertens F, Johansson B, Höglund M, Mitelman F: Chromosomal
imbalance maps of malignant solid tumors: a cytogenetic
survey of 3185 neoplasms. Cancer Res 1997, 57:2765-2780.
27. Muleris M, Salmon RJ, Dutrillaux B: Cytogenetics of colorectal
adenocarcinomas. Cancer Genet Cytogenet 1990, 46:143-156.
28. Ghadimi BM, Grade M, Liersch T, Langer C, Siemer A, Fuzesi L,
Becker H: Gain of chromosome 8q23-24 is a predictive
marker for lymph node positivity in colorectal cancer. Clin
Cancer Res 2003, 9:1808-1814.
29. Registry Norwegian Cancer: Cancer in Norway.  http://www
kreftregisteret no/ 2001.
30. Diep CB, Parada LA, Teixeira MR, Eknæs M, Nesland JM, Johansson B,
Lothe RA: Genetic profiling of colorectal cancer liver metas-
tases by combined comparative genomic hybridization and
G-banding analysis. Genes Chromosomes Cancer 2003, 36:189-197.
31. Culliford AT, Brooks AD, Sharma S, Saltz LB, Schwartz GK, O'Reilly
EM, Ilson DH, Kemeny NE, Kelsen DP, Guillem JG, Wong WD,
Cohen AM, Paty PB: Surgical debulking and intraperitoneal
chemotherapy for established peritoneal metastases from
colon and appendix cancer. Ann Surg Oncol 2001, 8:787-795.
32. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J,
Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL,
Francois Y, Vignal J, Gilly FN: Peritoneal carcinomatosis from
non-gynecologic malignancies: results of the EVOCAPE 1
multicentric prospective study. Cancer 2000, 88:358-363.
33. Alcock HE, Stephenson TJ, Royds JA, Hammond DW: Analysis of
colorectal tumor progression by microdissection and com-
parative genomic hybridization.  Genes Chromosomes Cancer
2003, 37:369-380.
34. Georgiades IB, Curtis LJ, Morris RM, Bird CC, Wyllie AH: Hetero-
geneity studies identify a subset of sporadic colorectal can-
cers without evidence for chromosomal or microsatellite
instability. Oncogene 1999, 18:7933-7940.
Additional data file 1
CGH copy number changes of different tumor stages in colorectal cancer. 
Complete CGH profiles of 10 primary carcinomas, 14 local recurrences, 
7 peritoneal carcinomatoses, and 42 liver metastases from colorectal can-
cer patients.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-3-6-S1.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/6
Page 9 of 9
(page number not for citation purposes)
35. He QJ, Zeng WF, Sham JS, Xie D, Yang XW, Lin HL, Zhan WH, Lin
F, Zeng SD, Nie D, Ma LF, Li CJ, Lu S, Guan XY: Recurrent genetic
alterations in 26 colorectal carcinomas and 21 adenomas
from Chinese patients. Cancer Genet Cytogenet 2003, 144:112-118.
36. Leung SY, Yuen ST, Chan TL, Chan AS, Ho JW, Kwan K, Fan YW,
Hung KN, Chung LP, Wyllie AH: Chromosomal instability and
p53 inactivation are required for genesis of glioblastoma but
not for colorectal cancer in patients with germline mismatch
repair gene mutation. Oncogene 2000, 19:4079-4083.
37. Chan TL, Curtis LC, Leung SY, Farrington SM, Ho JW, Chan AS, Lam
PW, Tse CW, Dunlop MG, Wyllie AH, Yuen ST: Early-onset color-
ectal cancer with stable microsatellite DNA and near-diploid
chromosomes. Oncogene 2001, 20:4871-4876.
38. Richter H, Slezak P, Walch A, Werner M, Braselmann H, Jaramillo E,
Ost A, Hirata I, Takahama K, Zitzelsberger H: Distinct chromo-
somal imbalances in nonpolypoid and polypoid colorectal
adenomas indicate different genetic pathways in the devel-
opment of colorectal neoplasms. Am J Pathol 2003, 163:287-294.
39. Leslie A, Carey FA, Pratt NR, Steele RJ: The colorectal adenoma-
carcinoma sequence. Br J Surg 2002, 89:845-860.
40. Hermsen M, Postma C, Baak J, Weiss M, Rapallo A, Sciutto A, Roe-
men G, Arends JW, Williams R, Giaretti W, De Goeij A, Meijer G:
Colorectal adenoma to carcinoma progression follows mul-
tiple pathways of chromosomal instability.  Gastroenterology
2002, 123:1109-1119.
41. Korn WM, Yasutake T, Kuo WL, Warren RS, Collins C, Tomita M,
Gray JW, Waldman FM: Chromosome arm 20q gains and other
genomic alterations in colorectal cancer metastatic to liver,
as analyzed by comparative genomic hybridization and fluo-
rescence in situ hybridization. Genes Chromosomes Cancer 1999,
25:82-90.
42. Platzer P, Upender MB, Wilson K, Willis J, Lutterbaugh JD, Nosrati A,
Willson JK, Mack D, Ried T, Markowitz SD: Silence of chromo-
somal amplifications in colon cancer.  Cancer Res 2002,
62:1134-1138.
43. Thorstensen L, Qvist H, Nesland JM, Giercksky KE, Lothe RA: Allel-
otype profiles of local recurrences and distant metastases
from colorectal-cancer patients. Int J Cancer 1996, 69:452-456.
44. Griffin CA, Lazar S, Hamilton SR, Giardiello FM, Long P, Krush AJ,
Booker SV: Cytogenetic analysis of intestinal polyps in polypo-
sis syndromes: comparison with sporadic colorectal
adenomas. Cancer Genet Cytogenet 1993, 67:14-20.
45. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Lep-
pert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic altera-
tions during colorectal-tumor development. N Engl J Med 1988,
319:525-532.
46. Cho KR, Fearon ER: DCC: linking tumor suppressor genes and
altered cell surface interactions in cancer? Curr Opin Genet Dev
1995, 5:72-78.
47. Arends JW: Molecular interactions in the Vogelstein model of
colorectal carcinoma. J Pathol 2000, 190:412-416.
48. McLeod HL, Murray GI: Tumour markers of prognosis in color-
ectal cancer. Br J Cancer 1999, 79:191-203.
49. Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson
BJ, Moon-Tasson L, Mahoney MR, Sargent DJ, O'Connell MJ, Witzig
TE, Farr G.H.,Jr, Goldberg RM, Thibodeau SN: Microsatellite insta-
bility and 8p allelic imbalance in stage B2 and C colorectal
cancers. J Natl Cancer Inst 1999, 91:1295-1303.
50. Bomme L, Lothe RA, Bardi G, Fenger C, Kronborg O, Heim S:
Assessments of clonal composition of colorectal adenomas
by FISH analysis of chromosomes 1, 7, 13 and 20. Int J Cancer
2001, 92:816-823.
51. Kunkel LM, Smith KD, Boyer SH, Borgaonkar DS, Wachtel SS, Miller
OJ, Breg WR, Jones HW, Rary JM: Analysis of human Y-chromo-
some-specific reiterated DNA in chromosome variants. Proc
Natl Acad Sci USA 1977, 74:1245-1249.
52. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Wald-
man F, Pinkel D: Comparative genomic hybridization for
molecular cytogenetic analysis of solid tumors. Science 1992,
258:818-821.
53. Kraggerud SM, Szymanska J, Abeler VM, Kaern J, Eknæs M, Heim S,
Teixeira MR, Trope CG, Peltomäki P, Lothe RA: DNA copy
number changes in malignant ovarian germ cell tumors. Can-
cer Res 2000, 60:3025-3030.
54. ISCN:  An International System for Human Cytogenetic Nomenclature
Mitelman F.th edition. Basel, Karger; 1995. 
55. Dysvik B, Jonassen I: J-Express: exploring gene expression data
using Java. Bioinformatics 2001, 17:369-370.